Please assess the completion status of the following clinical trial:

Trial Title: Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Previously diagnosed (e.g. more than 6 months ago) primary or secondary adrenal insufficiency with a stable daily glucocorticoid substitution dose for at least 3 months prior to study entry~* Signed informed consent to participate in the study~Exclusion Criteria:~* acute primary or secondary adrenal insufficiency~* clinical or laboratory signs of significant cerebral, cardiovascular, respiratory, hepatobiliary, pancreatic disease~* clinically significant renal dysfunction~* any medication with agents which could interfere with glucocorticoid kinetics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Plenadren (Type: EXPERIMENTAL): Plenadren (modified release hydrocortison) 20-25 or 30 mg oral tablets will be administered once-daily at 8.00 AM in the fasting state The dose is kept the same as patients had before entering the trial.
- Conventional glucocorticoid therapy (Type: ACTIVE_COMPARATOR): Hydrocortisone (dose range 10 to 30) mg will be continued as before entering the study. Cortisone Acetate (dose 25 to 37.5 mg) will be continued as before entering the study. The morning dose will be administered in the fasting state.~The total daily dose and timing is not changed during the study period.
- Healthy volunteers (Type: NO_INTERVENTION): Healthy volunteers will be enrolled as control group

Based on this trial design, predict the completion outcome and termination type (if applicable).